FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Etoposide Injection
Status: Currently in Shortage
»Date first posted: 01/24/2018
»Therapeutic Categories: Oncology

Expand all

Accord Healthcare Inc. (Revised 02/23/2018)

Company Contact Information:
800-843-7477

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
ETOPOSIDE INJ USP 20MG/ML 5ML (NDC 16729-114-31) Partial availability from the week of 3/5/2018. Full recovery expected April 2018. Increase demand for the product
ETOPOSIDE INJ USP 20MG/ML (Nova Plus) 5ML (NDC 16729-262-31) Partial availability from the week of 4/2/2018. Full recovery expected mid-April 2018 Increase demand for the product
ETOPOSIDE INJ. USP 20MG/ML 25 ML (NDC 16729-114-08) Partial availability from the week of 3/5/2018. Full recovery expected mid-April 2018 Increase demand for the product
ETOPOSIDE INJ. USP 20MG/ML 50 ML (NDC 16729-114-11) Partial availability from the week of 2/29/2018. Full recovery expected mid-April 2018 Increase demand for the product

Fresenius Kabi USA, LLC (Reverified 02/15/2018)

Company Contact Information:
888-386-1300

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
100 mg per 5 mL, 20 mg per mL, MDV (NDC 63323-104-05) Backordered. Next release anticipated February 2018. Manufacturing delay
500 mg per 25 mL, 20 mg per mL, MDV (NDC 63323-104-25) Backordered. Next release anticipated March 2018. Manufacturing delay
1 gram per 50 mL, 20 mg per mL, MDV (NDC 63323-104-50) Backordered. Next release anticipated late January 2018. Manufacturing delay

Teva Pharmaceuticals (New 01/24/2018)

Company Contact Information:
800-545-8800

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
100 mg / 5 mL Multiple-dose Vials (NDC 0703-5653-01) Teva has limited inventory and an unusual excess of product orders has created a backlog in fulfillment. Teva is expecting resupply of finished product in February 2018 that is expected to meet current supply demand for 1 - 2 months. Shortage of an active ingredient
500 mg / 25 mL Multiple-dose Vials (NDC 0703-5656-01) Teva has limited inventory and an unusual excess of product orders has created a backlog in fulfillment. Teva is expecting resupply of finished product in February 2018 that is expected to meet current supply demand for 1 - 2 months. Shortage of an active ingredient
1 gram /50 mL Multiple-dose Vials (NDC 0703-5657-01) Marketing 50 mL size is not planned for an undetermined period of time. Shortage of an active ingredient

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English